FDA outlines steps for individualized drug development

被引：0

|

作者：

Asher Mullard

机构：

来源：

Nature Reviews Drug Discovery | 2021年 / 20卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：91 / 91

相关论文

共 50 条

[31] FDA nanotechnology report outlines scientific, regulatory challenges
不详
JOURNAL OF ENVIRONMENTAL HEALTH, 2008, 70 (06) : 60 - 60
[32] Drug development - Lupus drug company asks FDA for second chance
Couzin, J
SCIENCE, 2005, 307 (5711) : 835 - 835
[33] Newborns and drug studies: The NICHD/FDA newborn drug development initiative
Giacoia, GP
Mattison, DR
CLINICAL THERAPEUTICS, 2005, 27 (06) : 796 - 813
[34] Drug Development in Inflammatory Bowel Disease: The Role of the FDA
Lahiff, Conor
Kane, Sunanda
Moss, Alan C.
INFLAMMATORY BOWEL DISEASES, 2011, 17 (12) : 2585 - 2593
[35] Janet Woodcock discusses the FDA and the drug development process
Watson, C
DRUG DISCOVERY TODAY, 2004, 9 (13) : 548 - 550
[36] FDA announces two initiatives to accelerate drug development
不详
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (02) : 95 - 95
[37] NCI/FDA program to streamline cancer drug development
不详
JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (08) : 52N - 52N
[38] DEVELOPMENT OF A COURSE OF STUDY IN FDA DRUG REGULATORY PROCEDURES
JACOBS, RW
KING, JC
AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION, 1977, 41 (02) : 185 - 188
[39] FDA looks at key issues in drug development process
Sedlak, BJ
GENETIC ENGINEERING NEWS, 2004, 24 (09): : 1 - +
[40] Drug development and the FDA's critical path initiative
Woosley, R. L.
Cossman, J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (01) : 129 - 133

← 1 2 3 4 5 →